TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26681272
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no TachoSil patch)
Study: 24275775
Drug: Mepivacaine 2%
Normalized name: mepivacaine 2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 2% with epinephrine (10 µg/mL), injected at 5.4 mL (54 µg epinephrine) for group I and 10.8 mL (108 µg epinephrine) for group II.
Study: 24275775
Drug: Mepivacaine 2%
Normalized name: mepivacaine 2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 2% with epinephrine (108 µg) in group II.
Study: 24275775
Drug: Mepivacaine 2%
Normalized name: mepivacaine 2% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepivacaine 2% with epinephrine (54 µg) in group I.
Study: 23676529
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy + Selective Serotonin Reuptake Inhibitor (CBT+SSRI)
Study: 20639274
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle programme (e.g. physical exercise, smoking cessation, dietary advice, including stress management)
Study: 16603428
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (flare-up) protocol
Study: 7824809
Drug: Formoterol, inhaled,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol, inhaled, twice daily for 12 weeks
Study: 7824809
Drug: Salbutamol, inhaled,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, inhaled, four times daily for 12 weeks
Study: 28456146
Drug: Polypodium leucotomos/pomegranate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypodium leucotomos/pomegranate combination (PPmix®) 480 mg/day
Study: 28456146
Drug: Polypodium leucotomos
Normalized name: Polypodium leucotomos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypodium leucotomos alone (Fernblock®) 480 mg/day
Study: 26297156
Drug: GnRH agonists
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonists (triptorelin injections of 0.1mg on the 4th and 6th day after progesterone introduction)
Study: 23663119
Drug: Resveratrol supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol supplementation (150 mg/day)
Study: 21724628
Drug: Daily interruption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily interruption of fentanyl and/or midazolam infusions for up to 6 hours
Study: 16961787
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 mg to 100 mg daily, titrated by week 4)
Study: 3531295
Drug: Captopril 25
Normalized name: captopril 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 25 mg plus hydrochlorothiazide 15 mg
Study: 28708420
Drug: 1.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/kg BW Tualang Honey (high honey; HH; n=10)
Study: 28708420
Drug: 0.75 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75 g/kg BW Tualang Honey (low honey; LH; n=10)
Study: 22804826
Drug: Quadriderm cream
Normalized name: Cuadriderma
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Quadriderm cream
Study: 18217459
Drug: Rice policosanol
Normalized name: POLICOSANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice policosanol 10 mg/day
Study: 9549666
Drug: Modafinil and
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Modafinil and Methylphenidate (combination)
Study: 8045961
Drug: Goserelin (GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (GnRH agonist) for 9 months
Study: 2648890
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 100 mg suppository
Study: 29738179
Drug: Gujing Maisiha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gujing Maisiha Tablets combined with natural vitamin E
Study: 16828803
Drug: D-cycloserine (DCS)
Normalized name: D-Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D-cycloserine (DCS) 50 or 500 mg
Study: 15176649
Drug: Etanercept 25
Normalized name: etanercept 25 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 25 mg subcutaneously twice weekly for 12 weeks
Study: 2285719
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline epidural solution
Study: 31140402
Drug: Early endovenous
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early endovenous ablation (compression therapy and superficial endovenous ablation within 2 weeks of randomisation)
Study: 31140402
Drug: Deferred endovenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred endovenous ablation (compression therapy followed by endovenous ablation once the ulcer had healed)
Study: 24356398
Drug: Full periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full periodontal therapy (Group 1, n = 15)
Study: 17945291
Drug: Desmopressin combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin combined with 0.5 mg/kg furosemide daily
Study: 10190788
Drug: Paclitaxel 1-hour
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 1-hour infusion
Study: 10190788
Drug: Paclitaxel 3-hour
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 3-hour infusion
Study: 31460771
Drug: Panchatikta Ghrita
Normalized name: Ghrita Kumari Flower
DrugBank: Aloe vera flower (DB14254)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panchatikta Ghrita (PG) with calcium and vitamin D3 supplements
Study: 31460771
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D3 supplements
Study: 28510346
Drug: Rivipansel 4
Normalized name: Rivipansel
DrugBank: Rivipansel (DB12778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivipansel 4 g by intravenous infusion over 20 minutes
Study: 19906312
Drug: Multi-disciplinary orientation
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-disciplinary orientation program including face-to-face introduction to hospital facilities, multi-disciplinary team, treatment side effects, and self-care strategies.
Study: 16984385
Drug: DN-101 (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: DN-101 (high dose calcitriol) with docetaxel
Study: 15259289
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg 17beta-estradiol combined with 1, 2 or 3 mg drospirenone daily
Study: 15259289
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg drospirenone
Study: 10790458
Drug: Asthma education
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma education and medical treatment in the setting of a tertiary care pediatric allergy clinic with monthly contact from an asthma outreach nurse.
Study: 8379858
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel (1.25 g)
Study: 8379858
Drug: Estradiol gel
Normalized name: ESTRADIOL 1 mg in 1 g TOPICAL GEL [Estradiol Gel]
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol gel (2.5 g)
Study: 29354970
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at the twelve jing-well points (20 treatments, once a day) combined with bladder function training
Study: 29354970
Drug: Routine clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine clinical medication and bladder function training
Study: 21698665
Drug: 100 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 µg of 17β-estradiol (with cyclic progesterone) transdermally for 18 months
Study: 21698665
Drug: Incremental low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Incremental low-dose oral ethinyl-estradiol (3.75 µg daily from 0 to 6 months, 7.5 µg from 6 to 12 months, 11.25 µg from 12 to 18 months)
Study: 1385295
Drug: Isoprinosine (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoprinosine (500 mg twice daily)
Study: 18444146
Drug: 400-mcg/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400-mcg/day of Se
Study: 18444146
Drug: 200-mcg/day of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200-mcg/day of Se
Study: 16490580
Drug: Sitagliptin 25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25, 50, 100, 200, or 400 mg QD for 10 days
Study: 16490580
Drug: Sitagliptin 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 800 mg on day 1 followed by 600 mg QD on days 3 to 10
Study: 16490580
Drug: Sitagliptin 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 300 mg BID for 10 days
Study: 11368283
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (e.g., betamethasone sodium phosphate, beclomethasone dipropionate, fluticasone propionate, budesonide)
Study: 11368283
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (e.g., beclomethasone dipropionate, flunisolide, budesonide)
Study: 2458659
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia + assumed blockade of prostaglandin synthesis, blockade of receptors for histamine1, histamine2 and serotonin2, and inhibition of fibrinolysis with indomethacin, astemizole, ranitidine, ketanserin and tranexamic acid
Study: 25496342
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi combined with conventional rehabilitation therapies
Study: 25496342
Drug: Standard conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard conventional rehabilitation therapies
Study: 22825094
Drug: Self-administered misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered misoprostol (400 μg vaginally or buccally 3-4 hours before IUD insertion)
Study: 22825094
Drug: Self-administered misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered misoprostol
Study: 18996858
Drug: Cyclosporine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (2.5 mg x kg(‐1)d(‐1)) plus low-calorie diet
Study: 16186076
Drug: black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: black cohosh 160 mg daily
Study: 16186076
Drug: multibotanical (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: multibotanical (50 mg black cohosh, alfalfa, chaste tree, dong quai, false unicorn, licorice, oats, pomegranate, Siberian ginseng, boron) four capsules daily
Study: 16186076
Drug: conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: conjugated equine estrogen 0.625 mg +/- 2.5 mg medroxyprogesterone acetate
Study: 12517545
Drug: Morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine sulphate (MS)
Study: 1325853
Drug: AVP antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AVP antagonist (10 micrograms/kg body weight i.v.)
Study: 1325853
Drug: Nicotine infusion
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine infusion (1.0 micrograms/kg body weight per min)
Study: 1325853
Drug: AVP antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: AVP antagonist (5 micrograms/kg i.v.)
Study: 1325853
Drug: Nicotine infusion
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine infusion plus AVP antagonist i.v.
Study: 6238558
Drug: Metaproterenol (MP)
Normalized name: MP-0250
DrugBank: MP-0250 (DB17218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (MP) 1.5 mg four times a day
Study: 27007793
Drug: Alternative antihypertensive
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative antihypertensive regimen
Study: 20154294
Drug: Developmental formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Developmental formulations of paracetamol (acetaminophen)
Study: 20154294
Drug: Commercial products
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial products of paracetamol (acetaminophen)
Study: 20154294
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (developmental and commercial)
Study: 10472325
Drug: Acyclovir (ACV)
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acyclovir (ACV) 15 mg/kg i.v. over one hour every 8 hours for 42 doses
Study: 10472325
Drug: Valacyclovir (VCV)
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valacyclovir (VCV) 2 g every 8 hours for a total of 42 doses (after switching from ACV)
Study: 3908330
Drug: Aluminum ibuprofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum ibuprofen suspension (200 mg)
Study: 3908330
Drug: Acetaminophen with
Normalized name: acetaminophen with codeine ORAL ELIXIR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen with codeine elixir (240 mg and 24 mg)
Study: 26679630
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (5 capsules daily providing 2.0 g/d EPA and 1.0 g/d DHA)
Study: 15755229
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity treatment
Study: 12460128
Drug: Cannabis abuse
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis abuse treatment
Study: 29804294
Drug: 10-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day high-dose proton pump inhibitor triple therapy (HD-PPI-TT) with 60 mg lansoprazole, 500 mg clarithromycin, and 1 g amoxicillin, each administered twice daily for 10 days
Study: 29804294
Drug: 10-day sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day sequential therapy (ST) with 30 mg lansoprazole and 1 g amoxicillin for 5 days followed by 30 mg lansoprazole, 500 mg clarithromycin, and 400 mg metronidazole for 5 days
Study: 29804294
Drug: 10-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day high-dose proton pump inhibitor triple therapy (HD-PPI-TT)
Study: 23241449
Drug: Double-masked supplementation
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-masked supplementation with either 30 mg Fe and 400 μg folic acid or 60 mg Fe and 400 μg folic acid
Study: 23888001
Drug: Prior treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior treatment with antipsychotic long-acting injection (LAI)
Study: 23888001
Drug: Clozapine (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (as a randomised treatment)
Study: 23888001
Drug: Non-clozapine oral
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Non-clozapine oral SGA (as a randomised treatment)
Study: 23888001
Drug: Switch from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from LAI to oral antipsychotic
Study: 16729916
Drug: Cilengitide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide at 2000 mg in patients with nonmetastatic androgen-independent prostate cancer
Study: 16729916
Drug: Cilengitide at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide at 500 mg or 2000 mg, intravenously twice weekly in patients with metastatic prostate cancer
Study: 23165810
Drug: NaCl solution
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl solution (Placebo)
Study: 18598095
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) 1180 mg/day
Study: 18598095
Drug: Thioctic acid
Normalized name: Thioctic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioctic acid 600 mg/day
Study: 15842525
Drug: Metformin 1
Normalized name: metformin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1 g orally
Study: 12160589
Drug: Alternating instillations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternating instillations of interferon‐alpha and BCG monthly for up to 1 year
Study: 25220046
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction programme (group therapy with a 5-day educational intervention and five 2-hour follow-up visits)
Study: 15081141
Drug: Riboflavin-containing microballoons
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riboflavin-containing microballoons (MB) administered orally
Study: 12171452
Drug: Calcium supplement
Normalized name: Calcium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplement containing 1,000 mg supplemental calcium as calcium citrate malate (n=7)
Study: 8105778
Drug: Group treatment
Normalized name: Allergenic Extracts Intradermal Kit [9 SO. GRASS GROUP TREATMENT SET]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group treatment with cognitive therapy followed by exposure in vivo
Study: 8105778
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (cognitive-behavioral treatment)
Study: 3802928
Drug: Diltiazem (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.2, 0.3, and 0.4 mg/kg body weight, followed by infusion of 2, 3, and 4 micrograms/kg/min)
Study: 31695323
Drug: Dexmedetomidine (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.1 µg/kg/h)
Study: 26611473
Drug: Rituximab added
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab added to fludarabine and cyclophosphamide chemotherapy
Study: 20399952
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (200 mcg every 6 hours after initial 400 mcg vaginally)
Study: 20399952
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (initial 400 mcg, then 200 mcg every 6 hours)
Study: 17613583
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of calcium/vitamin D supplements and exercise/protein
Study: 12844328
Drug: Subcutaneous melagatran
Normalized name: melagatran
DrugBank: Melagatran (DB13616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous melagatran
Study: 12844328
Drug: Individualised dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised dosage based on creatinine clearance or bodyweight
Study: 11095442
Drug: Alendronate treatment
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate treatment for 3-4 years
Study: 8720425
Drug: Felodipine 10
Normalized name: felodipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine 10 mg extended-release (ER)
Study: 1304448
Drug: Moclobemide 150
Normalized name: moclobemide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moclobemide 150 mg t.i.d.
Study: 3113974
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone releasing factor (hGRF-44 NH2) administered intravenously at doses of 2.5-80 micrograms, 80-320 micrograms, and 75-600 micrograms
Study: 31219706
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a median dose of 42 Gy/6 fractions (range 25 - 54 Gy/6#)
Study: 19485591
Drug: Education support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education support treatment
Study: 15590533
Drug: Anticoagulant/antiaggregating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant/antiaggregating agents
Study: 15590533
Drug: Fibrinolytic/thrombolytic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinolytic/thrombolytic agents
Study: 8173688
Drug: Felodipine-Metoprolol combination
Normalized name: felodipine / metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine-Metoprolol combination tablet
Study: 30355865
Drug: Aurolab aqueous
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aurolab aqueous drainage implant (AADI)
Study: 24025111
Drug: Sodium valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium valproate 500 mg daily (or 400 mg daily by intravenous infusion) for 7 days
Study: 22858044
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine 10 mL and morphine 1.5mg (Group B+Mor)
Study: 22858044
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine 10 mL and magnesium 500 mg (Group B+Mg)
Study: 22858044
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine 10 mL morphine 1.5mg and magnesium 500 mg (Group B+Mor+Mg)
Study: 22858044
Drug: 0.1% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% bupivacaine 10 mL (Group B)
Study: 20181257
Drug: Restrictive intraoperative
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive intraoperative intravenous fluid administration (Group A)
Study: 20181257
Drug: Liberal intraoperative
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal intraoperative intravenous fluid administration (Group B)